

Table 7.6h
Persistency of Discharge Regimen by Follow-up Period, 2003 to 2007
Recipients with Pancreas After Kidney (PAK) Transplants

	Year of Transplant				
	2003	2004	2005	2006	2007
Discharge Regimen (w/ or w/o Steroid Use)					
CyA+Aza					
At Discharge (N)	1	-	-	-	1
At Discharge (%)	100.0%	-	-	-	100.0%
6 Months PostTx (%)	0.0%	-	-	-	100.0%
1 Year PostTx (%)	0.0%	-	-	-	-
2 Years PostTx (%)	0.0%	-	-	-	-
3 Years PostTx (%)	0.0%	-	-	-	-
CyA+MMF					
At Discharge (N)	19	18	13	7	6
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	100.0%
6 Months PostTx (%)	68.4%	88.9%	69.2%	85.7%	50.0%
1 Year PostTx (%)	57.9%	71.4%	53.8%	85.7%	50.0%
2 Years PostTx (%)	46.8%	65.5%	30.8%	85.7%	-
3 Years PostTx (%)	46.8%	65.5%	30.8%	85.7%	-
CyA+Siro					
At Discharge (N)	4	7	5	6	1
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	100.0%
6 Months PostTx (%)	75.0%	71.4%	60.0%	83.3%	100.0%
1 Year PostTx (%)	50.0%	42.9%	20.0%	83.3%	100.0%
2 Years PostTx (%)	50.0%	14.3%	0.0%	66.7%	-
3 Years PostTx (%)	25.0%	14.3%	0.0%	66.7%	-
Siro+MMF					
At Discharge (N)	6	9	5	2	1
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	100.0%
6 Months PostTx (%)	83.3%	75.0%	80.0%	100.0%	100.0%
1 Year PostTx (%)	83.3%	62.5%	60.0%	100.0%	100.0%
2 Years PostTx (%)	83.3%	62.5%	40.0%	100.0%	-
3 Years PostTx (%)	66.7%	50.0%	40.0%	-	-
Tac+Aza					
At Discharge (N)	1	1	3	-	1
At Discharge (%)	100.0%	100.0%	100.0%	-	100.0%
6 Months PostTx (%)	100.0%	100.0%	33.3%	-	0.0%
1 Year PostTx (%)	0.0%	100.0%	33.3%	-	0.0%
2 Years PostTx (%)	0.0%	0.0%	33.3%	-	0.0%
3 Years PostTx (%)	0.0%	0.0%	33.3%	-	0.0%
Tac+MMF					
At Discharge (N)	208	239	217	190	190
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	100.0%
6 Months PostTx (%)	74.2%	79.4%	87.5%	90.5%	89.5%

(Continued)

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Regimen change is defined as being on different drug combination at follow-up comparing to discharge, or indication of conflicting regimen (CyA vs. Tac; MMF/MPA vs. Aza; Siro vs. Evero) during follow-up period, or graft failure/death. Addition or deletion of steroids is not considered a regimen change.

Rates are calculated for the most common discharge regimens.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.

See Technical Notes for further details.

Table 7.6h (Continued)
Persistency of Discharge Regimen by Follow-up Period, 2003 to 2007
Recipients with Pancreas After Kidney (PAK) Transplants

	Year of Transplant				
	2003	2004	2005	2006	2007
Discharge Regimen (w/ or w/o Steroid Use)					
Tac+MMF					
1 Year PostTx (%)	63.1%	71.3%	80.5%	82.9%	83.1%
2 Years PostTx (%)	54.8%	62.5%	69.0%	74.2%	74.8%
3 Years PostTx (%)	50.0%	56.5%	62.1%	74.2%	-
Tac+Siro					
At Discharge (N)	26	33	21	21	-
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	-
6 Months PostTx (%)	65.4%	75.2%	65.2%	76.2%	-
1 Year PostTx (%)	49.5%	59.5%	65.2%	71.4%	-
2 Years PostTx (%)	31.7%	56.2%	55.1%	71.4%	-
3 Years PostTx (%)	27.2%	52.9%	41.4%	-	-

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Regimen change is defined as being on different drug combination at follow-up comparing to discharge, or indication of conflicting regimen (CyA vs. Tac; MMF/MPA vs. Aza; Siro vs. Evero) during follow-up period, or graft failure/death. Addition or deletion of steroids is not considered a regimen change.

Rates are calculated for the most common discharge regimens.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.

See Technical Notes for further details.